Why the study?
Pooled prognostic estimates for anaemia in HFpEF predate the contemporary LVEF >=50% definition and combine legacy with contemporary cohorts.
Does WHO-defined anaemia increase all-cause mortality in patients with heart failure with preserved ejection fraction?
Population
109 909 HFpEF patients across 17 cohort studies
Comparison
Binary WHO-defined anaemia vs no anaemia
Design
Systematic review and meta-analysis
Follow-up
12-72 months
Key result
WHO-defined anaemia is independently associated with a higher risk of all-cause mortality in contemporary heart failure with preserved ejection fraction (LVEF ≥50%) (aHR 1.41; 95% CI 1.26-1.57).
Authors
Loading...
Anaemia may refine mortality risk stratification in HFpEF; extends meta-analytic support to contemporary LVEF ≥50% cohorts while leaving treatment effects open.
Meta-Analysis (n=109,909)
Does WHO-defined anaemia increase all-cause mortality in patients with heart failure with preserved ejection fraction?
Hazard Ratio: 1.41 (95% CI 1.26–1.57)
WHO-defined anaemia is independently associated with a ~40-50% higher all-cause mortality in HFpEF, a finding that remains robust under the contemporary LVEF ≥50% definition.
Tripathi et al. (2026) conducted a meta-analysis in Heart failure with preserved ejection fraction (HFpEF) (n=109,909). WHO-defined anaemia vs. No anaemia was evaluated on All-cause mortality (aHR 1.41, 95% CI 1.26-1.57). WHO-defined anaemia is independently associated with a higher risk of all-cause mortality in contemporary heart failure with preserved ejection fraction (LVEF ≥50%) (aHR 1.41; 95% CI 1.26-1.57).